* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download No Slide Title
Mental status examination wikipedia , lookup
Spectrum disorder wikipedia , lookup
Political abuse of psychiatry wikipedia , lookup
Mental disorder wikipedia , lookup
Recovery International wikipedia , lookup
Classification of mental disorders wikipedia , lookup
Antipsychotic wikipedia , lookup
Pyotr Gannushkin wikipedia , lookup
Narcissistic personality disorder wikipedia , lookup
Bipolar disorder wikipedia , lookup
Diagnostic and Statistical Manual of Mental Disorders wikipedia , lookup
Schizoaffective disorder wikipedia , lookup
Major depressive disorder wikipedia , lookup
Dissociative identity disorder wikipedia , lookup
Generalized anxiety disorder wikipedia , lookup
Moral treatment wikipedia , lookup
Child psychopathology wikipedia , lookup
History of psychiatric institutions wikipedia , lookup
History of mental disorders wikipedia , lookup
Bipolar II disorder wikipedia , lookup
History of psychiatry wikipedia , lookup
Abnormal psychology wikipedia , lookup
Emergency psychiatry wikipedia , lookup
Controversy surrounding psychiatry wikipedia , lookup
Depression in childhood and adolescence wikipedia , lookup
The Treatment of Patients with Mood Disorders and Substance Use Disorders Roger D. Weiss, MD Chief, Division of Alcohol and Drug Abuse, McLean Hospital Professor of Psychiatry, Harvard Medical School Belmont, MA, USA Likelihood of SUDs in people with psychiatric diagnoses (ECA) Diagnosis Bipolar disorder Schizophrenia Panic disorder Major depression Anxiety disorder Odds ratio 6.6 4.6 2.9 1.9 1.7 SUD in bipolar disorder Lower ■ More medication adherence Relapses ■ Hospitalizations ■ Homelessness ■ Suicide ■ Substance abuse in patients with psychiatric illness Enhanced reinforcement Mood change Escape Hopelessness Poor judgment Inability to appreciate consequences The Self-Medication Hypothesis Intolerance of specific emotions The importance of a “drug of choice” More useful in describing substance use rather than dependence Diagnosing Psychiatric Disorders in Patients with SUDs How long should you wait until a patient has been off all drugs and alcohol before you can diagnose any psychiatric disorder? How much does diagnosis or primary vs. secondary depression matter? Treatment of patients with SUD and mood disorder Pharmacotherapy Psychosocial treatment Pharmacotherapy Co-occurring disorder pharmacotherapy Typically focuses on treatment of the psychiatric disorder, though more recent studies have focused on SUD as well Choice of medication is typically based on the usual considerations Side effect profile Family history of medication response Likelihood of medication adherence McLean Hospital Study of Gender, Mood, and Recovery from Alcohol Dependence (Greenfield et al., 1998) Followed 101 patients (60 men, 41 women) hospitalized for alcohol dependence Monthly assessment visits x 1 year SCID diagnoses of MDD were made a) regardless of drinking and b) > 3 mos. abstinent Depression and Gender as Predictors of Time to Relapse Chance of No Relapse 1.00 0.75 0.50 Female, not dep Male, not dep 0.25 0.00 Male, dep Female, dep 0 50 100 150 200 Days Since Study Entry 250 300 Relation of Depression and Discharge Antidepressants to Time to First Drink Chances of Abstinence 1.00 0.75 No dep, no discharge antidep 0.50 No dep, discharge antidep 0.25 Dep, discharge antidep Dep, no discharge antidep 0.00 0 50 100 150 200 Days Since Study Entry (Greenfield 250 et al., Arch Gen. Psychiatry, 1998) 300 Medication studies of co-occurring SUDs and mood disorders All trials have compared medication vs. placebo No head-to-head studies of 2 active medications Placebo Effect 1. 2. Very strong in substance dependent populations Difficult to distinguish between placebo effect & study participation effect, particularly in disorders involving voluntary behavior such as substance use disorders Drinks Per Day (ITT) Placebo 16 14 Mean Phone Call Initiation 12 In-Clinic Screen 10 Treatment Start 8 6 4 2 0 B13 B12 B11 B10 B9 B8 B7 B6 B5 B4 B3 B2 B1 1 2 3 4 5 6 7 8 9 10 11 12 Study Week 15 Pharmacotherapy of SUD & Depression Most recent controlled studies show improvement in depression Tricyclics have most robust effect SSRIs most helpful in late-onset alcoholics, may worsen early-onset alcoholics Less improvement in substance use (often correlated with mood improvement), but not worsening (ie, not enabling) Pneumonia model Valproate for Alcohol Dependence & BD 24-week trial of valproate vs. placebo in 59 pts on lithium Valproate patients had Fewer heavy drinking days Less drinking on heavy drinking days No differences in manic, depressive sx Salloum et al., 2005 Medication adherence in patients with BD & SUD Patients with BD & SUD were asked about lifetime adherence to various medications Answers ranged from “never” to “all the time” We compared “all the time” to other responses Weiss et al., 1998 Lifetime adherence 100 % adherence Lithium* Valproate* Benzodiazepines Neuroleptics TCAs SSRIs 22 % 48 % 36 % 37 % 63 % 46 % *Lithium vs. valproate p< .03 Reasons for med non-adherence Lithium n=29 Physical effects ■ Saw no need for meds ■ Wanted to use substances Valproate ■ “Hassle” to take (lab tests) n=13 ■ Forgot ■ Wanted to use Benzodiazepines ■ Took more to get “high” n=21 ■ Impatient, so took more ■ Couldn’t think clearly ■ Reasons for non-adherence (cont’d) Neuroleptics ■ Physical effects (EPS) n=19 TCAs n=10 SSRIs n=17 ■ Impatient, modify substance use, or get high ■ Saw no need ■ Impatient, so took more ■ Saw no need ■ Meds not working, so took less ■ Wanted to use ■ Felt manic ■ Meds not working, so took less Psychosocial Treatment Models of dual diagnosis treatment Sequential Parallel Integrated Models of integrated treatment Depends on the disorders & their relationship “Integrated” treatment means different things to different people Integrated Group Therapy (IGT): Core principles Cognitive-behavioral model focuses on parallels between the disorders in recovery/relapse thoughts and behaviors Interaction between the disorders The single disorder paradigm: “bipolar substance abuse” The central recovery rule IGT structure Check-in: substance use, mood, med adherence Review last week’s group Skill practice Didactic/handout on integrated topic (e.g., dealing with depression without using alcohol and drugs) Discussion What is “integrated” about Integrated Group Therapy ? Check-in focuses on mood, substance use, and medication adherence Topics relevant to both disorders Patients seen as having a single disorder: “bipolar substance abuse” Relationship & similarities between the disorders & the recovery process stressed Integrated Group Therapy: Sample topics Dealing with depression without using alcohol or drugs Denial, ambivalence, acceptance Taking medication Self-help groups (for both SUD & BD) Identifying and fighting triggers Getting a good night’s sleep The Central Recovery Rule No matter what Don’t drink Don’t use drugs Take your medication as prescribed No matter what! Findings of IGT research 3 studies funded by National Institute on Drug Abuse Compared IGT initially to either treatment as usual or standard manualized Group Drug Counseling (GDC) All 3 studies showed significantly greater likelihood of abstinence in IGT patients Fewer differences in mood outcomes “Community-Friendly” Version of IGT vs. Group Drug Counseling Making IGT more “community-friendly” IGT had had 2 successful studies, with 20 sessions led by therapists who had CBT and BD knowledge However, many community treatment programs don’t have counselors with experience in either CBT or BD, and can’t be paid for 20-session treatments These factors could reduce adoption of IGT in community treatment programs Study of “Community-Friendly” version of IGT Made IGT more “community-friendly” 12 sessions, instead of 20 Groups were run by front-line drug counselors without formal CBT training or explicit BD knowledge Compared IGT to GDC Weiss et al., Drug and Alcohol Dependence, 2009 Patients 61 patients: 31 IGT & 30 GDC Current BD & substance dependence Substance A use in the past 60 days mood stabilizer regimen for ≥ 2 weeks Results: Mood (p<.10) Outcome Variables IGT (n=31) End of 3-mo Baseline Tx f/u GDC (n=30) End of 3-mo Baseline tx f/u Mood episode (% yes) 52 20 27 57 30 37 Depressive episode 35 20 20 40 23 22 Manic episode 16 0 7 17 7 15 Time to first abstinent month by treatment (p<.04) Abstinent (%) 100 80 IGT 60 40 GDC 20 0 Baseline 1 2 3 Month 4 5 6 Abstinence: IGT vs. GDC ≥1 month abstinent: 71% vs. 40 %, p<.02 Abstinent throughout treatment (3 mos.): 36% vs. 13%, p<.05 “Good clinical outcome” by treatment condition: Abstinent & no mood episodes in last month Good outcome (%) 50 40 IGT 30 IGT 20 GDC GDC 10 0 End of treatment (p<.04)* 6 month follow-up Conducting an IGT Group Structure of a 60-min. IGT session (15’) Review of last week’s group (5’) Review of last week’s skill practice (5’) Discuss session topic (20’) Review session hand-out and wrap up (10’) Hand out and discuss skill practice for next week (5’) Check-in/introductions Conducting the check-in Have you used drugs or alcohol during the past week? If so, on how many days? How was your overall mood during the past week? Did you take all of your medications as prescribed during the past week? If no, why not? Did you face any high-risk situations or triggers in the past week? If yes, how did you deal with them? Conducting the check-in (2) Asking about how many days of use is important Allows for assessment of improvement vs. worsening Conducting the check-in (3) The check-in establishes the tone of the group It illustrates the “integrated” nature of IGT Listen for the relevance of check-ins to the session topic Come back to check-ins to illustrate session topic themes Key principles of IGT Parallels between the two disorders in the recovery and relapse processes Interactions between the two disorders The single disorder paradigm: “bipolar substance abuse” The central recovery rule Parallels in the recovery and relapse processes The abstinence violation effect vs. stopping medication when depressed Parallels in the recovery and relapse processes Recovery vs. relapse thoughts and behaviors “May as well thinking” vs. “It matters what you do” Medication non-adherence vs. staying in bed all day vs. skipping AA Combating hopelessness: “It matters what you do” • • • • Early sign of relapse to depression: not returning phone calls One more call vs. one less call to make Making concrete suggestions for taking one step at a time toward recovery You’re always on the road to getting better or getting worse; therefore, it matters what you do Interactions between the two disorders Why use the term “bipolar substance abuse?” “Drinking is bad for your mood” “Playing around with your medication is bad for your addiction” General guidelines for conducting IGT Go back and forth between mood issues and substance use issues Think about parallels: if a patient is talking about drinking, think about mood issues, and vice versa Try to gently call on everyone, including people who are lost in their own thoughts Be upbeat General guidelines for conducting IGT (cont) Focus on both successes and failures (“What did you do on the 4 days that you were sober that you didn’t do on the 3 days that you drank?)” Therapist characteristics for IGT Familiarity with SUD, BD ideal Can be successfully run by front-line substance abuse counselors Some knowledge of relapse prevention or CBT is very helpful Empathic Warm, friendly, non-confrontational Who should be in an IGT group? Willingness to enter a group that addresses both problems Not acutely manic Not intoxicated IGT is designed to be delivered with pharmacotherapy as well; other psychosocial treatment is also encouraged Adapting IGT to other settings Change the length of the sessions Add items to the check-in (e.g., exercise, self-help meeting attendance) Add a preparation group Broaden the population Recite the central recovery rule at the end of the group Use IGT principles in individual Rx Current status of IGT Has been adapted for patients with psychotic illness as well In use in multiple clinical settings at McLean Hospital Currently in use in multiple clinical and research settings in U.S., Canada Book published in 2011 by Guilford Press Now available!